Biomolecules & Therapeutics

  • 제21권3호
  • /
  • Pages.204-209
  • /
  • 2013
  • /
  • 1976-9148(pISSN)
  • /
  • 2005-4483(eISSN)
한국응용약물학회 (The Korean Society of Applied Pharmacology)
권호 표지
DOI QR코드

DOI QR Code

Transglutaminase-2 Is Involved in Expression of Osteoprotegerin in MG-63 Osteosarcoma Cells

  • 투고 : 2013.04.25
  • 심사 : 2013.05.22
  • 발행 : 2013.05.31
PDF 다운로드
⟨ 이전 논문 다음 논문 ⟩

초록

Osteoprotegerin (OPG) is a secreted glycoprotein and a member of the tumor necrosis factor receptor superfamily. It usually functions in bone remodeling, by inhibiting osteoclastogenesis through interaction with a receptor activator of the nuclear factor ${\kappa}B$ (RANKL). Transglutaminases-2 (Tgase-2) is a group of multifunctional enzymes that plays a role in cancer cell metastasis and bone formation. However, relationship between OPG and Tgase-2 is not studied. Therefore, we investigated the involvement of 12-O-Tetradecanoylphorbol 13-acetate in the expression of OPG in MG-63 osteosarcoma cells. Interleukin-$1{\beta}$ time-dependently induced OPG and Tgase-2 expression in cell lysates and media of the MG-63 cells by a Western blot. Additional 110 kda band was found in the media of MG-63 cells. 12-O-Tetradecanoylphorbol 13-acetate also induced OPG and Tgase-2 expression. However, an 110 kda band was not found in TPA-treated media of MG-63 cells. Cystamine, a Tgase-2 inhibitor, dose-dependently suppressed the expression of OPG in MG-63 cells. Gene silencing of Tgase-2 also significantly suppressed the expression of OPG in MG-63 cells. Next, we examined whether a band of 110 kda of OPG contains an isopeptide bond, an indication of Tgase-2 action, by monoclonal antibody specific for the isopeptide bond. However, we could not find the isopeptide bond at 110 kda but 77 kda, which is believed to be the band position of Tgase-2. This suggested that 110 kda is not the direct product of Tgase-2's action. All together, OPG and Tgase-2 is induced by IL-$1{\beta}$ or TPA in MG-63 cells and Tgase-2 is involved in OPG expression in MG-63 cells.

키워드

참고문헌

  1. Augoulea, A., Vrachnis, N., Lambrinoudaki, I., Dafopoulos, K., Iliodromiti, Z., Daniilidis, A., Varras, M., Alexandrou, A., Deligeoroglou, E. and Creatsas, G. (2013) Osteoprotegerin as a marker of ath-erosclerosis in diabetic patients. Int. J. Endocrinol. 2013, 182060.
  2. Brandstrom, H., Jonsson, K. B., Vidal, O., Ljunghall, S., Ohlsson, C. and Ljunggren, O. (1998) Tumor necrosis factor-alpha and -beta upregulate the levels of osteoprotegerin mRNA in human osteosarcoma MG-63 cells. Biochem. Biophys. Res. Commun. 248, 454-457. https://doi.org/10.1006/bbrc.1998.8993
  3. Cross, S. S., Yang, Z., Brown, N. J., Balasubramanian, S. P., Evans, C. A., Woodward, J. K., Neville-Webbe, H. L., Lippitt, J. M., Reed, M. W., Coleman, R. E. and Holen, I. (2006) Osteoprotegerin (OPG)--a potential new role in the regulation of endothelial cell phenotype and tumour angiogenesis? Int. J. Cancer 118, 1901-1908. https://doi.org/10.1002/ijc.21606
  4. De Toni, E. N., Thieme, S. E., Herbst, A., Behrens, A., Stieber, P., Jung, A., Blum, H., Goke, B. and Kolligs, F. T. (2008) OPG is regulated by beta-catenin and mediates resistance to TRAIL-induced apoptosis in colon cancer. Clin. Cancer Res. 14, 4713-4718. https://doi.org/10.1158/1078-0432.CCR-07-5019
  5. Emery, J. G., McDonnell, P., Burke, M. B., Deen, K. C., Lyn, S., Silverman, C., Dul, E., Appelbaum, E. R., Eichman, C., DiPrinzio, R., Dodds, R. A., James, I. E., Rosenberg, M., Lee, J. C. and Young, P. R. (1998) Osteoprotegerin is a receptor for the cytotoxic ligand TRAIL. J. Biol. Chem. 273, 14363-14367. https://doi.org/10.1074/jbc.273.23.14363
  6. Fisher, J. L., Thomas-Mudge, R. J., Elliott, J., Hards, D. K., Sims, N. A., Slavin, J., Martin, T. J. and Gillespie, M. T. (2006) Osteoprotegerin overexpression by breast cancer cells enhances orthotopic and osseous tumor growth and contrasts with that delivered therapeutically. Cancer Res. 66, 3620-3628. https://doi.org/10.1158/0008-5472.CAN-05-3119
  7. Heath, D. J., Downes, S., Verderio, E. and Griffi n, M. (2001) Characterization of tissue transglutaminase in human osteoblast-like cells. J. Bone Miner. Res. 16, 1477-1485. https://doi.org/10.1359/jbmr.2001.16.8.1477
  8. Higashikawa, F., Eboshida, A. and Yokosaki, Y. (2007) Enhanced biological activity of polymeric osteopontin. FEBS Lett. 581, 2697-2701. https://doi.org/10.1016/j.febslet.2007.05.018
  9. Holen, I., Croucher, P. I., Hamdy, F. C. and Eaton, C. L. (2002) Osteoprotegerin (OPG) is a survival factor for human prostate cancer cells. Cancer Res. 62, 1619-1623.
  10. Johnson, K., Svensson, C. I., Etten, D. V., Ghosh, S. S., Murphy, A. N., Powell, H. C. and Terkeltaub, R. (2004) Mediation of spontaneous knee osteoarthritis by progressive chondrocyte ATP depletion in Hartley guinea pigs. Arthritis Rheum. 50, 1216-1225. https://doi.org/10.1002/art.20149
  11. Johnson, K. A., Polewski, M. and Terkeltaub, R. A. (2008) Transglutaminase 2 is central to induction of the arterial calcifi cation program by smooth muscle cells. Circ. Res. 102, 529-537. https://doi.org/10.1161/CIRCRESAHA.107.154260
  12. Johnson, K. A. and Terkeltaub, R. A. (2005) External GTP-bound transglutaminase 2 is a molecular switch for chondrocyte hypertrophic differentiation and calcifi cation. J. Biol. Chem. 280, 15004-15012. https://doi.org/10.1074/jbc.M500962200
  13. Kaartinen, M. T., Murshed, M., Karsenty, G. and McKee, M. D. (2007) Osteopontin upregulation and polymerization by transglutaminase 2 in calcifi ed arteries of Matrix Gla protein-defi cient mice. J. Histochem. Cytochem. 55, 375-386.
  14. Kobayashi-Sakamoto, M., Hirose, K., Isogai, E. and Chiba, I. (2004) NF-kappaB-dependent induction of osteoprotegerin by Porphyromonas gingivalis in endothelial cells. Biochem. Biophys. Res. Commun. 315, 107-112. https://doi.org/10.1016/j.bbrc.2004.01.024
  15. Kondo, H., Guo, J. and Bringhurst, F. R. (2002) Cyclic adenosine monophosphate/protein kinase A mediates parathyroid hormone/parathyroid hormone-related protein receptor regulation of osteoclastogenesis and expression of RANKL and osteoprotegerin mRNAs by marrow stromal cells. J. Bone Miner. Res. 17, 1667-1679. https://doi.org/10.1359/jbmr.2002.17.9.1667
  16. Lambert, C., Oury, C., Dejardin, E., Chariot, A., Piette, J., Malaise, M., Merville, M. P. and Franchimont, N. (2007) Further insights in the mechanisms of interleukin-1beta stimulation of osteoprotegerin in osteoblast-like cells. J. Bone Miner. Res. 22, 1350-1361. https://doi.org/10.1359/jbmr.070508
  17. Lee, H. L., Park, M. K., Bae, H. C., Yoon, H. J., Kim, S. Y., Lee, C. H. and Lee, C. H. (2012) Transglutaminase-2 is involved in all-trans retinoic acid-induced invasion and matrix metalloproteinases expression of SH-SY5Y neuroblastoma cells via NF-$\kappa B$ pathway. Biomol. Ther. 20, 286-292. https://doi.org/10.4062/biomolther.2012.20.3.286
  18. Lorand, L. and Graham, R. M. (2003) Transglutaminases: crosslinking enzymes with pleiotropic functions. Nat. Rev. Mol. Cell Biol. 4, 140-156. https://doi.org/10.1038/nrm1014
  19. McCarthy, H. S., Williams, J. H., Davie, M. W. and Marshall, M. J. (2009) Platelet-derived growth factor stimulates osteoprotegerin production in osteoblastic cells. J. Cell. Physiol. 218, 350-354. https://doi.org/10.1002/jcp.21600
  20. Mhaouty-Kodja, S. (2004) Ghalpha/tissue transglutaminase 2: an emer ging G protein in signal transduction. Biol. Cell 96, 363-367. https://doi.org/10.1111/j.1768-322X.2004.tb01427.x
  21. Mori, K., Le Goff, B., Berreur, M., Riet, A., Moreau, A., Blanchard, F., Chevalier, C., Guisle-Marsollier, I., Leger, J., Guicheux, J., Masson, M., Gouin, F., Redini, F. and Heymann, D. (2007) Human osteosarcoma cells express functional receptor activator of nuclear factorkappa B. J. Pathol. 211, 555-562. https://doi.org/10.1002/path.2140
  22. Nurminskaya, M., Magee, C., Faverman, L. and Linsenmayer, T. F. (2003) Chondrocyte-derived transglutaminase promotes maturation of preosteoblasts in periosteal bone. Dev. Biol. 263, 139-152. https://doi.org/10.1016/S0012-1606(03)00445-7
  23. Osorio, A., Ortega, E., Torres, J. M., Sanchez, P. and Ruiz-Requena, E. (2013) Biochemical markers of vascular calcifi cation in elderly hemodialysis patients. Mol. Cell. Biochem. 374, 21-27. https://doi.org/10.1007/s11010-012-1500-y
  24. Park, M. K., Lee, H. J., Shin, J., Noh, M., Kim, S. Y. and Lee, C. H. (2011) Novel participation of transglutaminase-2 through c-Jun Nterminal kinase activation in sphingosylphosphorylcholine-induced keratin reorganization of PANC-1 cells. Biochim. Biophys. Acta 1811, 1021-1029. https://doi.org/10.1016/j.bbalip.2011.07.007
  25. Park, M. K., Park, Y., Shim, J., Lee, H. J., Kim, S. and Lee, C. H. (2012) Novel involvement of leukotriene B(4) receptor 2 through ERK activation by PP2A down-regulation in leukotriene B(4)-induced keratin phosphorylation and reorganization of pancreatic cancer cells. Biochim. Biophys. Acta 1823, 2120-2129. https://doi.org/10.1016/j.bbamcr.2012.09.004
  26. Rosenthal, A. K., Derfus, B. A. and Henry, L. A. (1997) Transglutaminase activity in aging articular chondrocytes and articular cartilage vesicles. Arthritis Rheum. 40, 966-970. https://doi.org/10.1002/art.1780400526
  27. Schneeweis, L. A., Willard, D. and Milla, M. E. (2005) Functional dissection of osteoprotegerin and its interaction with receptor activator of NF-kappaB ligand. J. Biol. Chem. 280, 41155-41164. https://doi.org/10.1074/jbc.M506366200
  28. Shipman, C. M. and Croucher, P. I. (2003) Osteoprotegerin is a soluble decoy receptor for tumor necrosis factor-related apoptosis-inducing ligand/Apo2 ligand and can function as a paracrine survival factor for human myeloma cells. Cancer Res. 63, 912-916.
  29. Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M. S., Luthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., Shimamoto, G., DeRose, M., Elliott, R., Colombero, A., Tan, H. L., Trail, G., Sullivan, J., Davy, E., Bucay, N., Renshaw-Gegg, L., Hughes, T. M., Hill, D., Pattison, W., Campbell, P., Sander, S., Van, G., Tarpley, J., Derby, P., Lee, R. and Boyle, W. J. (1997) Osteoprotegerin: a novel secreted protein involved in the regulation of bone density. Cell 89, 309-319. https://doi.org/10.1016/S0092-8674(00)80209-3
  30. Speer, M. Y., Chien, Y. C., Quan, M., Yang, H. Y., Vali, H., McKee, M. D. and Giachelli, C. M. (2005) Smooth muscle cells defi cient in osteopontin have enhanced susceptibility to calcifi cation in vitro. Cardiovasc. Res. 66, 324-333. https://doi.org/10.1016/j.cardiores.2005.01.023
  31. Thirunavukkarasu, K., Miles, R. R., Halladay, D. L., Yang, X., Galvin, R. J., Chandrasekhar, S., Martin, T. J. and Onyia, J. E. (2001) Stimulation of osteoprotegerin (OPG) gene expression by transforming growth factor-beta (TGF-beta). Mapping of the OPG promoter region that mediates TGF-beta effects. J. Biol. Chem. 276, 36241-36250. https://doi.org/10.1074/jbc.M104319200
  32. Truneh, A., Sharma, S., Silverman, C., Khandekar, S., Reddy, M. P., Deen, K. C., McLaughlin, M. M., Srinivasula, S. M., Livi, G. P., Marshall, L. A., Alnemri, E. S., Williams, W. V. and Doyle, M. L. (2000) Temperature-sensitive differential affi nity of TRAIL for its receptors. DR5 is the highest affi nity receptor. J. Biol. Chem. 275, 23319-23325. https://doi.org/10.1074/jbc.M910438199
  33. Tsuda, E., Goto, M., Mochizuki, S., Yano, K., Kobayashi, F., Morinaga, T. and Higashio, K. (1997) Isolation of a novel cytokine from human fi broblasts that specifi cally inhibits osteoclastogenesis. Biochem. Biophys. Res. Commun. 234, 137-142. https://doi.org/10.1006/bbrc.1997.6603
  34. Vidal, O. N., Sjogren, K., Eriksson, B. I., Ljunggren, O. and Ohlsson, C. (1998) Osteoprotegerin mRNA is increased by interleukin-1 alpha in the human osteosarcoma cell line MG-63 and in human osteoblast-like cells. Biochem. Biophys. Res. Commun. 248, 696-700. https://doi.org/10.1006/bbrc.1998.9035
  35. Winther, S., Christensen, J. H., Flyvbjerg, A., Schmidt, E. B., Jorgensen, K. A., Skou-Jorgensen, H. and Svensson, M. (2013) Osteoprotegerin and mortality in hemodialysis patients with cardiovascular disease. Clin Nephrol. [Epub ahead of print]
  36. Yasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Goto, M., Mochizuki, S. I., Tsuda, E., Morinaga, T., Udagawa, N., Takahashi, N., Suda, T. and Higashio, K. (1999) A novel molecular mechanism modulating osteoclast differentiation and function. Bone 25, 109-113. https://doi.org/10.1016/S8756-3282(99)00121-0
  37. Zauli, G., Melloni, E., Capitani, S. and Secchiero, P. (2009). Role of full-length osteoprotegerin in tumor cell biology. Cell. Mol. Life Sci. 66, 841-851. https://doi.org/10.1007/s00018-008-8536-x

피인용 문헌

  1. Inhibition of tissue transglutaminase promotes Aβ-induced apoptosis in SH-SY5Y cells vol.37, pp.12, 2016, https://doi.org/10.1038/aps.2016.95
  2. Transglutaminase-2 is Involved in Cell Apoptosis of Osteosarcoma Cell Line U2OS Under Hypoxia Condition vol.72, pp.1, 2015, https://doi.org/10.1007/s12013-014-0451-1
  3. TGM2 knockdown reverses cisplatin chemoresistance in osteosarcoma vol.42, pp.4, 2013, https://doi.org/10.3892/ijmm.2018.3753